

# 4<sup>th</sup> NordiQC Conference on Applied Immunohistochemistry

June 2<sup>nd</sup> - 5<sup>th</sup> 2020, Aalborg Congress & Culture Centre, Aalborg, Denmark



## PROGRAMME

draft 29.1.2020

### Tuesday 2<sup>nd</sup> June 2020

	14:00 – 18:30	<i>Registration</i>
<b>A</b>	14:30 – 18:15	<b>Industrial symposium – news and scientific updates</b> Short scientific presentations from exhibitors
	18:30 – 20:00	<i>Informal get-together buffet, AKKC</i>

### Wednesday 3<sup>rd</sup> June 2020

	08:00 – 09:00	<i>Registration</i>
<b>B</b>	09:00 – 09:30	<b>Welcome – The NordiQC Challenge</b> <i>Mogens Vyberg: NordiQC External Quality Assurance in IHC (25 + 5 min)</i>
<b>C</b>	09:30 – 10:30	<b>Keynote lecture</b> <i>Allen Gown: Evolution and transformation of IHC (50 + 10 min)</i>
	10:30 – 11:00	<i>Coffee. Exhibitions and posters</i>
<b>D</b>	11:00 – 12:45	<b>Progress in standardization of IHC</b> <i>Carol Cheung: Evolution of quality assurance for IHC (50 + 10 min)</i> <i>Paul Swanson: Current issues in validation of IHC (40 + 5 min)</i>
	12:45 – 13:45	<i>Lunch. Exhibitions and posters</i>
<b>E</b>	13:45 – 15:45	<b>Tumour classification I – Undifferentiated and Carcinoma</b> <i>Andrew Bellizzi: IHC approach for the undifferentiated neoplasm. Markers to choose and markers to leave (40 + 5 min)</i> <i>Mogens Vyberg: EQA of 'undifferentiated' marker analyses (10 + 5 min)</i> <i>Andrew Bellizzi: IHC approach to identification of primary site of carcinomas presenting at metastatic site (40 + 5 min)</i> <i>Mogens Vyberg: EQA of carcinoma marker analyses (10 + 5 min)</i>
	15:45 – 16:00	<i>Coffee. Exhibitions and posters</i>
<b>F</b>	16:00 – 17:15	<b>Tumour classification II – soft tissue tumours</b> <i>Paul Swanson: Paul Swanson: State of the art for IHC and biomarker testing in soft tissue tumours (50 + 5 min)</i> <i>Rasmus Røge: EQA of soft tissue tumour marker analyses (15 + 5 min)</i>
	18:00 – 19:30	<i>Reception at Kunsten Museum of Modern Art Aalborg</i>

### Thursday 4<sup>th</sup> June 2020

<b>G</b>	08:30 – 10:30	<b>Tumour classification III – Breast cancer</b> <i>Megan Troxell: State of the art for biomarker testing in breast cancer (40 + 5 min)</i> <i>Anne-Vibeke Lænkholm: Results from the Danish Breast Cancer Group (20 + 5 min)</i> <i>Rasmus Røge: Update on Ki67 IHC – what, how and why? (20 + 5 min.)</i>
----------	---------------	----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

	<b>Thursday 4<sup>th</sup> ...</b> 08:30 – 10:30	<i>Megan Troxell</i> : Diagnostic IHC applications in breast cancer (20 + 5 min)
	10:30 – 11:00	<i>Coffee. Exhibitions and posters</i>
<b>G</b>  <b>H</b>	11:00 – 12:30	<b>Tumour classification III – Breast cancer (cont.)</b> <i>Rasmus Røge</i> : EQA of breast cancer marker analyses (15 + 5 min) <b>Predictive markers – PD-L1 and others</b> <i>Hans-Ulrich Schildhaus</i> : Update of the PD-L1 testing landscape. What have we being doing, what are we doing and what to come? (30 + 5 min) <i>Allen Gown</i> : The PD-L1 challenge in daily practice (30 + 5 min)
	12:30 – 13:30	<i>Lunch. Exhibitions and posters</i>
<b>H</b>  <b>I</b>	13:30 – 15:30	<b>Predictive markers – PD-L1 and others (cont.)</b> <i>Emina Torlakovic</i> : PD-L1 assay interchangeability (25 + 5 min) <i>Søren Nielsen</i> : EQA of PD-L1 testing (25 + 5 min) <i>Carol Cheung</i> : Emerging predictive markers: ROS1 and NTRK (25 + 5 min) <b>The NordiQC Challenge</b> <i>Søren Nielsen</i> : Seminal NordiQC EQA results during 20 years (25 + 5 min)
	15:30 – 15:45	<i>Coffee. Exhibitions and posters</i>
<b>J</b>	15:45 – 17:00	<b>Tumour classification IV – Malignant lymphoma</b> <i>Emina Torlakovic</i> : Contemporary role of IHC in lymphoma (50 + 5 min) <i>Michael Bzorek</i> : EQA of lymphoma markers (15 + 5 min)
	19:00 –	<i>Conference diner, Hotel Hvide Hus</i>

### Friday 5<sup>th</sup> June 2020

<b>K</b>	08:30 – 10:30	<b>Tumour classification V – Lung carcinoma and malignant mesothelioma</b> <i>Vasiliki Panou</i> : Malignant mesothelioma – risk factors and epidemiology; the asbestos history of Aalborg (25 + 5 min) <i>Keith Kerr</i> : IHC and other markers in the differential diagnosis of lung carcinoma vs. malignant mesothelioma (45 + 5 min) <i>Christos Meristoudis</i> : Malignant mesothelioma – reclassification of 600 Aalborg cases (15 + 5 min) <i>Ole Nielsen</i> : EQA of lung carcinoma and mesothelioma markers (15 + 5 min)
	10:30 – 10:45	<i>Coffee</i>
<b>K</b>	10:45 – 11:35	<b>Tumour classification V – Lung carcinoma and malignant mesothelioma (cont.)</b> <i>Keith Kerr</i> : PD-L1 in non-small cell lung cancer (NSCLC), an update (25 + 5 min) <i>Birgit Gulddammer Skov</i> : Histology vs cytology in PD-L1 testing for NSCLC (15 + 5 min)
<b>L</b>	11:35 – 12:55	<b>Tumour classification VI – Gastrointestinal and neuroendocrine neoplasias</b> <i>Andrew Bellizzi</i> : IHC for diagnosis and classification of gastrointestinal and neuroendocrine neoplasias (50 + 10 min) <i>Mogens Vyberg</i> : EQA of GI and NE neoplasia markers (15 + 5 min)
	12:55 – 13:00	<i>Mogens Vyberg</i> : Completion
	13:00	<i>Lunch – restaurant or to-go</i>